|Bid||343.41 x 2200|
|Ask||343.57 x 1400|
|Day's Range||342.55 - 347.56|
|52 Week Range||249.17 - 388.67|
|PE Ratio (TTM)||24.35|
|Earnings Date||Oct 22, 2018 - Oct 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||389.31|
In Q2 2018, Biogen’s (BIIB) SMA (spinal muscular atrophy) drug Spinraza reported global revenues of $423 million. Biogen is focused on increasing the adoption of Spinraza in the adult population by establishing adult treatment centers, creating awareness about the benefits of the therapy, and working to expand access to the drug. In Q2 2018, Spinraza saw a 20% sequential rise in the number of adult patients and a 10% sequential rise in the number of total patients in the United States.
Allergan’s (AGN) US General Medicines segment includes women’s health products, central nervous system products, anti-infective products, gastrointestinal products, and diversified brands.
Biogen expects to witness robust demand trends for Tecfidera in ex-US markets in 2018. In Q2 2018, Biogen’s Tecfidera reported revenues of ~$1.1 billion, a decline of 2% YoY (year-over-year) but a rise of 10% sequentially. Tecfidera also reported revenues of ~$261 million from the ROW (rest of world) markets, which is a rise of 11% YoY and a rise of 1% sequentially.
Allergan’s (AGN) US Specialized Therapeutics segment includes revenue from the US sales of specialized products, including eye care products, medical esthetics products, dermatology products, neuroscience products, and urology products.
In its Q2 2018 earnings conference call, Biogen (BIIB) updated its 2018 GAAP EPS guidance from the previously projected range of $22.20–$23.20 to $21.80–$22.40, which implies a YoY (year-over-year) rise of 83%–87%.
On July 25, Biogen (BIIB) and Eisai announced positive results from the Phase 2 study evaluating BAN2401, an investigational anti-amyloid-beta (or Aβ) protofibril antibody, in early Alzheimer’s disease (or AD) indication after 18 months of therapy. The patients also included those suffering from AD-related mild cognitive impairment as well as those with mild AD. The results from the Phase 2 trial seem to validate beta-amyloid as a potential target for treating Alzheimer’s disease.
Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs. Express Scripts is in talks with biotechnology companies Biomarin Pharmaceutical Inc (BMRN.O), Spark Therapeutics Inc (ONCE.O) and Bluebird Bio Inc (BLUE.O) to have its specialty pharmaceutical business exclusively distribute their new haemophilia therapies when they are expected to become available in 2019 and 2020, Chief Medical Officer Steve Miller told Reuters in an interview.
MARKET PULSE Hedge-fund giant Bridgewater Associates, with about $160 billion under management, has added 84,629 shares of Alibaba Group Holding Ltd. (baba) worth some $15.7 million, to its holdings, according to a regulatory filing on Tuesday.
Biogen's (BIIB.O) muscle disease treatment Spinraza has been deemed too expensive for use on Britain's state-run health service, even after a price discount offered by the U.S. drugmaker. Spinraza, which has a U.S. list price of $750,000 in the first year of treatment, is a big money-spinner in Biogen's home market.
Biogen's muscle disease treatment Spinraza has been deemed too expensive for use on Britain's state-run health service, even after a price discount offered by the U.S. drugmaker. Spinraza, which has a U.S. list price of $750,000 in the first year of treatment, is a big money-spinner in Biogen's home market.
Experts are questioning a major scientific theory of the disease, which could mean two Biogen drugs won’t be successful.
Biotech stocks have been hot since the beginning of May, rising by about 13% as measured by the iShares Nasdaq Biotechnology ETF ( IBB), more than double the pace of the S&P 500's rise. Shares of Intercept Pharmaceuticals Inc. ( ICPT) have risen by more than 63% since the beginning of May, while recently posting better-than-expected quarterly results that beat on both the top and bottom lines. The stock has run into a level of technical resistance around $118, posing as the first issue. Additionally, the relative strength index is showing signs that the stock is now overbought, rising above 70 three times since the start of June.
BeiGene (BGNE) released its second-quarter earnings on August 9. The company surpassed Wall Street analysts’ estimates for revenues but missed its EPS estimates. BeiGene reported adjusted EPS of -$2.92 on revenues of $52.8 million, compared to its estimated EPS of -$2.06 on revenues of $22.5 million. The chart below compares BeiGene’s revenues and EPS since the first quarter of 2017.
Sarepta Therapeutics (SRPT), a commercial-stage biopharmaceutical company, develops unique RNA-targeted therapeutics, gene therapies, and other medicines for neuromuscular diseases. It released its Q2 2018 earnings on August 8 and surpassed Wall Street analysts’ estimates for EPS and revenues. It reported adjusted EPS of -$0.43 on revenues of $73.5 million compared to the estimated EPS of -$0.89 on revenues of $71.6 million.
The following is our latest Fund Analyst Report for Primecap Odyssey Growth POGRX . Morningstar Premium Members have access to full analyst reports such as this for more than 1,000 of the largest and best mutual funds. Primecap Odyssey Growth is one of a select number of funds run by Primecap Management, whose fundamentals-based multimanager approach richly rewards long-term investors.
As discussed earlier, Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to revenues of $112 million during the second quarter of 2017. Ionis missed Wall Street analyst estimates for revenues and EPS in Q2 2018. Ionis reported commercial revenues of $57 million during Q2 2018, over 100% growth as compared to commercial revenues of $24 million during the second quarter of 2017.
The Street leans bullish on Biogen Inc (NASDAQ: BIIB ), and one sidelined analyst doesn’t want to miss on the profits. The Rating Stifel Nicolaus analyst Paul Matteis resumed coverage of Biogen with a ...
Wall Street analysts estimate Sarepta will report a net loss of $0.89 per share on revenues of $71.6 million in Q2 2018, which is more than a 100% YoY increase in revenues as compared to $35.0 million during the second quarter of 2017. Wall Street analyst estimates suggest the stock has the potential to return ~51.4% over the next 12 months. As of August 6, 19 analysts were tracking Sarepta Therapeutics stock.